MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
10.35
+0.31 (3.09%)
At close: May 19, 2026, 4:00 PM EDT
9.92
-0.43 (-4.14%)
After-hours: May 19, 2026, 5:04 PM EDT
MiNK Therapeutics Employees
MiNK Therapeutics had 15 employees as of December 31, 2025. The number of employees decreased by 8 or -34.78% compared to the previous year.
Employees
15
Change (1Y)
-8
Growth (1Y)
-34.78%
Revenue / Employee
n/a
Profits / Employee
-$831,329
Market Cap
51.56M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | -8 | -34.78% |
| Dec 31, 2024 | 23 | -8 | -25.81% |
| Dec 31, 2023 | 31 | -6 | -16.22% |
| Dec 31, 2022 | 37 | 4 | 12.12% |
| Dec 31, 2021 | 33 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Metagenomi Therapeutics | 119 |
| Xilio Therapeutics | 76 |
| aTyr Pharma | 60 |
| BeyondSpring | 44 |
| iBio, Inc. | 20 |
| Instil Bio | 14 |
| Cingulate | 14 |
INKT News
- 4 days ago - MiNK Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - MiNK Therapeutics Earnings release: Q1 2026 - Filings
- 4 days ago - MiNK Therapeutics Quarterly report: Q1 2026 - Filings
- 4 days ago - MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation - GlobeNewsWire
- 5 days ago - MiNK Therapeutics initiates agenT-797 clinical trial - TheFly
- 5 days ago - MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness - GlobeNewsWire
- 7 days ago - MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 - GlobeNewsWire
- 11 days ago - MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs - GlobeNewsWire